drugset
drugset / Trial / NCT02406261

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02406261 ↗

Phase 1 Completed 82 enrolled AstraZeneca Eli Lilly and Company · collab
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study

Timeline

Start
2015-04-30
Primary completion
2015-08-31
Completion
2015-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg Oral
Subject Lanabecestat Small molecule 50 mg Oral
Subject Midazolam Small molecule 250 ug Oral
Subject Midazolam Small molecule 500 ug Oral
Subject Simvastatin Small molecule 20 mg Oral

Indications

No indication recorded.